ArticleNature2024
Role of IL-27 in Epstein-Barr virus infection revealed by IL-27RA deficiency.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
9.1field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 38 citations in OpenAlex.
- Autosomal recessive OSMRβ deficiency: Connecting OSM and/or IL-31 with atopy.Journal of human immunity · 2026Article
- Local and circulating cytotoxic CD4medRxiv : the preprint server for health sciences · 2026Article
- Toward a monogenic architecture of human infections: From 1996 to 2026.Journal of human immunity · 2026Review
- Interleukin-27 remodels the bone marrow niche to suppress B-cell development and leukaemia progression in mouse models.EBioMedicine · 2026Article
- Reframing IL-27: a central regulator of CD8Trends in immunology · 2026Review
- Limited protection against early-life lung murine cytomegalovirus infection results from deficiency of cytotoxic CD8 T cells.PLoS pathogens · 2026Article
- Distinct EBV-Associated Phenotypes Due to a Novel Homozygous Missense Variant inbioRxiv : the preprint server for biology · 2026Article
- IL-27, a metabolic regulator secreted by astrocytes in response to GLP-1RA OHP2, modulates microglial reprogramming in Alzheimer's disease by regulating cGAS lactylation.Journal of neuroinflammation · 2026Article
- T-cell lymphoma-associated STAT3 variants impose a type 1 regulatory-like phenotype.Frontiers in immunology · 2026Article
- "Innovative diagnostics and treatments of infections in transplantation," report from the 2025Transplant international : official journal of the European Society for Organ Transplantation · 2026Article
- IL-27: A Double-Edged Sword in Immune Regulation via JAK-STAT Orchestration.Journal of immunology research · 2026Review
- IL-27 promotes Treg cell expression of CD122 and fitness at homeostasis.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- IL-27Ra promotes the progression of neonatal necrotizing enterocolitis.Scientific reports · 2025Article
- Epstein-Barr virus pathogenesis and emerging control strategies.Nature reviews. Microbiology · 2025Review
- The potential impacts of human genetics on virus emergence.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- CD4Nature immunology · 2025Article
- Article
- Pathological IgE Production in Inborn Errors of Immunity and Beyond.Immunological reviews · 2025Review
- Human immunity to fungal infections.The Journal of experimental medicine · 2025Review
- Integrative transcriptomic and single-cell analysis reveals IL27RA as a key immune regulator and therapeutic indicator in breast cancer.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 7 institutions in 4 countries.
Emmanuel MartinLaboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France.ORCID 0000-0003-4211-7373
Sarah WinterLaboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France.
Cécile Garcin *Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France.ORCID 0000-0001-9279-3690
Kay Tanita *Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France.
Akihiro Hoshino *Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France.
Christelle Lenoir *Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France.
Benjamin FournierLaboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France.
Mélanie MigaudLaboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Imagine Institute, Paris, France.ORCID 0000-0003-3062-1214
David BoutboulUniversité Paris Cité, Paris, France.ORCID 0000-0002-5006-8279
Mathieu SimoninLaboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France.ORCID 0000-0002-0448-8811
Alicia FernandesPlateforme Vecteurs Viraux et Transfert de Gènes, Institut Necker Enfants Malades, Necker-Enfants Malades Hospital, APHP, Paris, France.
Paul BastardUniversité Paris Cité, Paris, France.
Tom Le VoyerUniversité Paris Cité, Paris, France.ORCID 0000-0002-7253-3135
Anne-Laure RoupieLaboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France.
Yassine Ben AhmedLaboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France.
Marianne Leruez-VilleService de Bactériologie, Virologie, Parasitologie et Hygiène, Necker-Enfants Malades Hospital, Paris, France.
Marianne BurgardService de Bactériologie, Virologie, Parasitologie et Hygiène, Necker-Enfants Malades Hospital, Paris, France.
Geetha RaoGarvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia.
Cindy S MaGarvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia.ORCID 0000-0001-5387-8413
Cécile MassonPlateforme de Bioinformatique, INSERM UMR1163, Université de Paris, Imagine Institute, Paris, France.
Claire SoudaisLaboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France.ORCID 0000-0002-4387-6649
Capucine PicardLaboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France.
Jacinta BustamanteUniversité Paris Cité, Paris, France.
Stuart G TangyeGarvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia.ORCID 0000-0002-5360-5180
Nathalie CheikhHôpital Jean Minjoz, Centre Hospitalo-Universitaire de Besançon, Besançon, France.ORCID 0000-0002-3403-3842
Mikko SeppänenPediatric Research Center and Rare Disease Center, New Children's Hospital, University of Helsinki and HUS Helsinki University Hospital, Helsinki, Finland.ORCID 0000-0001-7547-0902
Anne PuelUniversité Paris Cité, Paris, France.ORCID 0000-0003-2603-0323
Mark DalyInstitut for Molecular Medecine Finland, University of Helsinki, Helsinki, Finland.
Jean-Laurent CasanovaUniversité Paris Cité, Paris, France.
Bénédicte NevenDepartment of Pediatric Immunology, Hematology and Rheumatology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
Alain FischerDepartment of Pediatric Immunology, Hematology and Rheumatology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
Sylvain LatourLaboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France. sylvain.latour@inserm.fr.ORCID 0000-0001-8238-4391
Inserm · FRHôpital Necker-Enfants Malades · FRGarvan Institute of Medical Research · AUUniversity of Helsinki · FICentre Hospitalier Universitaire de Besançon · FRInstitut Necker Enfants Malades · FRUniversité Paris Cité · FR
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epstein-Barr virus (EBV) infection can engender severe B cell lymphoproliferative diseases
Indexed as
Epstein-Barr Virus InfectionsInterleukin-27Receptors, InterleukinAdolescentAdultAllelesB-LymphocytesCD8-Positive T-LymphocytesChildChild, PreschoolFemaleFinlandGene FrequencyHerpesvirus 4, HumanHomozygoteHumansIL27RA protein, humanInterleukin-27InterleukinsMYDGF protein, humanReceptors, InterleukinSTAT1 protein, humanSTAT1 Transcription FactorSTAT3 protein, humanSTAT3 Transcription Factor
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.